IDEAYA Biosciences, Inc. (IDYA) Q1 2020 Earnings Results

IDEAYA Biosciences I Misses on EPS, Stock Down 3.3%

The earnings report indicates that IDEAYA Biosciences I is still in a development phase, as reflected by the negative EPS. The stock's 3.3% decline suggests that investors were disappointed with the results, particularly since no revenue figures were available. The lack of guidance may also contribute to uncertainty among investors about the company's short-term prospects.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.59	N/A	-3.51%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a cautious outlook while reaffirming their dedication to advancing their pipeline. They did not provide specific guidance for the upcoming quarters.

Management acknowledged the challenges faced during the quarter.

They emphasized ongoing commitment to their research and development efforts.

IDEAYA Biosciences I Misses on EPS, Stock Down 3.3%

Key numbers

Management commentary

IDEAYA Biosciences, Inc.

More earnings this week

IDEAYA Biosciences I Misses on EPS, Stock Down 3.3%

Key numbers

Management commentary